GSK Snaps Up US Biotech Rapt Therapeutics for $2.2bn
GSK just made its first big move under new boss Luke Miels—and it’s a chunky one….
-
-
GSK Shares Surge on Profit Upgrade Despite Tariff Uncertainty
GSK just gave investors a pleasant surprise. Shares jumped 3% to 1,705p Wednesday morning after the…
